

=> b reg
 FILE 'REGISTRY' ENTERED AT 16:29:25 ON 10 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2
 DICTIONARY FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 16

L4 STR



VAR G1=O/S

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 28


STEREO ATTRIBUTES: NONE
 L6 599 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 121210 ITERATIONS
 SEARCH TIME: 00.00.04

599 ANSWERS

=> d que sta 110

L4 STR




VAR G1=O/S

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

L6 599 SEA FILE=REGISTRY SSS FUL L4
 L8 STR



VAR G1=O/S

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

L10 170 SEA FILE=REGISTRY SUB=L6 SSS FUL L8

100.0% PROCESSED 599 ITERATIONS
 SEARCH TIME: 00.00.01

170 ANSWERS

=> b hcap

FILE 'HCAPLUS' ENTERED AT 16:29:34 ON 10 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jun 2008 VOL 148 ISS 24
FILE LAST UPDATED: 9 Jun 2008 (20080609/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr 114 tot

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STM
 AN 2007:438817 HCAPLUS
 DN 146:143450
 TI Preparation of gallium complexes of N-(carboxymethyl)azamacrocycles
 linked to biovectors as PET imaging agents
 IN Port, Marc; Corot, Claire; Gautheret, Thierry
 PA Guerbet, Fr.
 SO PCT Int. Appl., 91pp.
 CODEN: PIXX22
 DT Patent
 LA French
 FAN.CNT 3


PI	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	WG-2007042504	A2	20070419	2006WO-EP0067211	20061009
	WG-2007042504	A3	20080528		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, HR, HU, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, RW, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, ML, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GM, GL, MP, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	FR-2891823	A1	20070413	2006FR-000010289	20051007
	FR-289585	A1	20071012	2006FR-000002975	20060405
PPAI	2005FR-000010289	A	20051007		
	2006FR-000002975	A	20060405		
OS	NARPAT 146:143450				
CI					




AB The invention concerns gallium-68 compds. of formula Ch-L-B (chelate-linker-biovector), where Ch-Lp-Bq (p = q = 2-5), Ch is chosen from frameworks DTPA, DOTA, NOTA, DO3A, PC2A and their derive, having the general formula I (where M-M2-M3 form azamacrocycles N-(un)substituted with a variety of carboxymethyl groups which may be linked to biovectors (enzymes, cellular receptors, folate, etc.)). The invention also concerns methods for obtaining said compds., screening methods capable of selecting such compds. for chemical synthesis thereof and their diagnostic applications, in particular in PET, PET/MRI, PET/CT imaging.
 IT 306776-78-3 306776-79-4P
 RI: RCT (Reactant); SPH (Synthetic preparation); PREP (Preparation); PACT (Reactant or reagent)
 (preparation of gallium complexes of N-(carboxymethyl)azamacrocycles linked to biovectors as PET imaging agents)
 RN 306776-78-3 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 6-[3-oxo-3-(phenylmethoxy)propyl]-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STM
 AN 2002:267288 HCAPLUS
 DN 137:2480
 TI Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model
 AU Froidevaux, Sylvie; Eberle, Alex N.; Christe, Martine; Sumanovski, Lazar; Hoppeier, Axel; Schmitt, Jorg S.; Eisenwiener, Klaus; Beglinger, Christoph; Macke, Helmut R.
 SO Department of Research-ELF, University Hospital and University Children's Hospital, University of Basel, Basel, Switz.
 CS International Journal of Cancer (2002), 98(6), 930-937
 CODEN: IJCNAM; ISSN: 0020-7136
 PB Wiley-Liss, Inc.
 DT Journal
 LA English
 AB Somatostatin analogs labeled with radionuclides are of considerable interest in the diagnosis and therapy of SSTR-expressing tumors, such as gastroenteropancreatic, small cell lung, breast and frequently nervous system tumors. In view of the favorable phys. characteristics of the Ga isotopes 67Ga and 68Ga, enabling conventional tumor scintigraphy, PET and possibly internal radiotherapy, we focused on the development of a Ga-labeled somatostatin analog suitable for targeting SSTR-expressing tumors. For this purpose, 3 somatostatin analogs, OC, TOC and TATE were conjugated to the metal chelator DOTA and labeled with the radionuclides 111In, 90Y and 67Ga. They were then evaluated for their performance in the AR4-2J pancreatic tumor model by testing SSTR2-binding affinity, internalization/externalization in isolated cells and biodistribution in tumor-bearing nude mice. Surprisingly, we found that, compared to 111In or 90Y, labeling with 67Ga considerably improved the biol. performance of the tested somatostatin analogs with respect to SSTR2 affinity and tissue distribution. 67Ga-labeled DOTA-somatostatin analogs were rapidly excreted from nontarget tissues, leading to excellent tumor-to-nontarget tissue uptake ratios. Of interest for radiotherapeutic application, 67Ga-DOTA-TOC was strongly internalized by AR4-2J cells. Furthermore, our results suggest a link between the radioligand charge and its kidney retention. The excellent tumor selectivity of Ga-DOTA somatostatin analogs together with the different applications of Ga in nuclear oncol. suggests that Ga-DOTA somatostatin analogs will become an important tool in the management of SSTR-pos. tumors.
 IT 405263-91-4D, indium-111 complex
 RI: DGN (Diagnostic use); PHT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (67Ga- vs. 111In- and 90Y-labeled DOTA-somatostatin analogs for neuroendocrine tumor targeting)
 RN 405263-91-4 HCAPLUS
 CN L-Threonine, N-[4-carboxy-1-oxo-4-(1,4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysy-L-threonyl-L-cysteinyl-, cyclic (2-7)-disulfide (9CI) (CA INDEX NAME)

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)




RN 306776-79-4 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 6-(2-carboxyethyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)




L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)

PAGE 1-A




PAGE 2-A




RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE.FORMAT


L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)




PAGE 1-A




PAGE 2-A



L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)




RN 405263-89-0 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(1-(carboxymethyl)-5-(1,1-dimethylethoxy)-2-oxoethyl)-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)




L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)

RN 405263-91-4 HCAPLUS
 CN L-Threonine, N-[4-carboxy-1-oxo-4-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)butyl]-D-phenylalanyl-L-cysteiny-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteiny-L-, cyclic (2-7)-disulfide (9CI) (CA INDEX NAME)

PAGE I-A




PAGE 2-A




IT 306776-79-4P 405263-89-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of DOTA type azamacrocyclic prochelators for preparation of radiometal labeled mols. having improved biol. properties)
 RN 306776-79-4 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α-(2-carboxyethyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)

L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STM

AN 2000:619258 HCAPLUS
 DN 133:350200
 TI A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labeling
 AU Eisenwiener, K.-P.; Powell, P.; Macke, H. R.
 CS Department of Radiology, Institute of Nuclear Medicine, Division of Radiological Chemistry, University Hospital, Basel, CH-4031, Switz.
 SO Bioorganic & Medicinal Chemistry Letters (2000), 10(18), 2133-2135
 CODEN: BMCLDH; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 133:350200
 AB New DOTA-based bifunctional prochelators, e.g., 1-(1-carboxy-3-carbo-tert-butoxypropyl)-4,7,10-(carbo-tert-butoxymethyl)-1,4,7,10-tetraazacyclododecane (DOTAGA(tBu)4); (I) for a broad application in the modification of biomols. with metal ions were prepared. The five-step synthesis of I has an overall yield of about 20%. The coupling of I to a bioactive peptide on solid-phase was exemplified with use of a CCK-8 (cholecystokinin) analog.
 IT 306776-78-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of bifunctional prochelators for coupling to bioactive peptides for radiometal labeling)
 RN 306776-78-3 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α-[3-oxo-3-(phenylmethoxy)propyl]-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)



IT 306776-79-4P 306776-80-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of bifunctional prochelators for coupling to bioactive peptides for radiometal labeling)
 RN 306776-79-4 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α-(2-carboxyethyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 306776-80-7 HCAPLUS


L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN L-Phenylalaninamide, N-[(4-carboxy-1-oxo-4-{4,7,10-tris(carboxymethyl)-
 1,4,7,10-tetraazacyclododec-1-yl}butyl)-D- α -aspartyl-L-tyrosyl-L-
 norleucylglycyl-L-tryptophyl-L-norleucyl-L- α -aspartyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 128 tot


L28 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STM

L28 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)

AN 1999:736515 HCAPLUS
 DN 131:1351678
 TI Preparation of peptide derivatives for the imaging of angiogenic disorders
 IN Rajagadhye, Raju; Koduri, D. Scott; Harris, Thomas D.; Hemingway, Stuart
 J.; Lau, Shuang; Singh, Prahlad R.
 PA Du Pont Pharmaceuticals Company, USA
 SO PCT Int. Appl., 213 pp.
 CODEN: PXXD2
 DT Patent
 LA English
 FAH.CNT 8


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-----9558162	A2	19991118	1999WO-00006826	19990329 <--
WO-----9558162	A3	20000406		
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, AM, AE, BY, EG, KE, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA-----2324555	A1	19991118	1999CA-002324555	19990329 <--
AD-----9955417	A	19991129	1999AD-00055417	19990329 <--
EP-----1068224	A2	20010117	1999EP-000941944	19990329
EP-----1068224	B1	20050511		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
HU-----2001001468	A2	20010828	2001HU-000001468	19990329
BR-----9909400	A	20010925	1999BR-000009400	19990329
JP-----2000514641	T	20000521	2000JP-000548013	19990329
SE-----200000574	A	20021015	2000SE-00000574	19990329
AZ-----295369	T	20050515	1999AZ-000941944	19990329
ES-----2241313	T3	20051016	1999ES-000941944	19990329
US-----6322770	B1	20011127	1999US-000281207	19990330
US-20020015680	A1	20020207	1999US-000281209	19990330
US-----6524553	B2	20030125		
US-----6540663	B1	20030415	1999US-000281050	19990330
ZA-----2000004286	A	20010821	2000ZA-000004286	20000821
IN-2000NM00342	A	20070420	2000IN-MN0000342	20000830
NO-2000004917	A	20001102	2000NO-00004917	20000929
NO-2000RA09574	A	20010405	2000NO-00009574	20000929
US-20030124120	A1	20030703	2002US-000269252	20021031
US-20030149262	P	20030607	2002US-000306054	20021126
PRAI 1998US-00000150P	P	19980331		
1998US-00112715P	P	19981218		
1998US-00112732P	P	19981218		
1998US-00112829P	P	19981218		
1998US-00112831P	P	19981218		
1999WO-US0006826	W	19990329		
1999US-000281050	A3	19990330		
1999US-000281209	A3	19990330		

OS MARPAT 131:1351678
 AB Comps. (Q)d-Ln-Ch (Q is a peptide, de 1-10, ln is a linking group, Ch is a metal-bonding unit) were prepared for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel comps. useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. Thus, cyclo(Arg-Gly-Asp-D-Tyr-N-[2-[[[5-(carboxyl)-2-pyridinyl]hydrazono]methyl]benzenesulfonic acid]-3-aminopropyl)-Val) was prepared by acylation of cyclo(Arg-Gly-Asp-D-Tyr(3-aminopropyl)-Val) with 2-[[[5-[[[2,5-dioxo-1-pyridinyl]oxy]carbonyl]-2-pyridinyl]hydrazono]methyl]benzenesulfonic acid monosodium salt and converted into radiopharmaceutical 99mTc(VnA) (tricline) (phosphine), where VnA represents the vitronectin receptor antagonist.
 IT 192635-89-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of peptide derivs. for the imaging of angiogenic disorders)
 RN 192635-89-5 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
 1,7,10-tris(1,1-dimethylethyl) 4-(phenylmethyl) ester (CA INDEX NAME)



L28 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STM

AN 1999:442438 HCAPLUS
 DN 131:239827
 TI Radiometal-labeled macrocyclic chelator-derivatized somatostatin analogue
 with superb tumour-targeting properties and potential for
 receptor-mediated internal radiotherapy
 AU Heppeler, A.; Froidevaux, S.; Macke, H. R.; Jermann, E.; Behe, M.; Powell,
 P.; Hennig, M.
 SO Institute of Nuclear Medicine, Div. of Radiological Chemistry, University
 Hospital, Basel, CH-4031, Switz.
 CS Chemistry--A European Journal (1999), 5(7), 1974-1981
 CODEN: CEUJED; ISSN: 0947-6539
 PB Wiley-VCH Verlag GmbH
 DT Journal
 LA English
 AB A nonreactive DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
 acid) prochelator (4,7,10-tricarboxymethyl-tert-Bu ester
 1,4,7,10-tetraazacyclododecane-1-acetate) was synthesized which is useful
 in solid-phase and solution-phase peptide synthesis; it was coupled to the
 somatostatin analog Tyr3-Iys4(BOC)-octreotide. Deprotection in one step
 afforded DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC) in 66% yield.
 This peptide, modified with a chelator, was complexed with the radiometals
 67Ga3+, 111In3+ and 90Y3+ in high yields and with high specific
 activities. The three radioprecipitates show high stability in human serum
 and high affinity to the somatostatin receptor: it is four to five times
 higher for 67Ga-DOTATOC compared to 90Y-DOTATOC and 111In-DOTATOC. The
 67Ga-labeled compound also shows significantly higher tumor and lower kidney
 uptake than the two congeners. 67Ga-DOTATOC was compared in patients with
 the com. available gold standard 111In-DTPA0-D-Phe1-octreotide. The new
 compound delineates SRIF-receptor pos. tumors very favorably and shows
 distinctly lower uptake by the kidneys. Evidently, the differences in the
 coordination chemical of the metals causes the differences in the biol.
 behavior. Indeed, a crystallog. study of the Ga3+ and Y3+ complexes of
 the model peptide DOTA-D-PheNH2 showed differences in the geometry of the
 complexes. The gallium complex is hexacoordinated with pseudooctahedral
 cis geometry and a folded macrocyclic unit. The equatorial plane is
 formed by two transannular nitrogens of the cyclen ring and two oxygens of
 the corresponding carboxylate groups. The two axial positions are formed
 by the two remaining ring nitrogen atoms. The amide carbonyl oxygen is not
 bound to the metal and one carboxylate group is free and most likely
 contributes to the favorable handling of the radioprecipitate by the kidneys.
 In contrast, the structure of Y-DOTA-D-PheNH2 has eight-fold coordination,
 and includes the amide carbonyl oxygen. The geometry is a compact and
 somewhat distorted square-antiprism with two almost perfect planes (N4 and
 O4) with a maximum deviation of 0.025 Å. The dihedral angle between the two
 planes is only 0.36°.
 IT 192635-89-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (radiometal-labeled macrocyclic chelator-derivatized somatostatin
 analog with tumor-targeting properties)
 RN 192635-89-5 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
 1,7,10-tris(1,1-dimethylethyl) 4-(phenylmethyl) ester (CA INDEX NAME)



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 16:30:23 ON 10 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 16:30:23 ON 10 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:30:23 ON 10 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr 129 tot
```

```

129 ANSWER 1 OF 2 USPATFULL ON 57N
AN 2007:288696 USPATFULL
IN PRESSURE TANK FITTING ASSEMBLY
IN Cress, Ronald D., Indianapolis, IN, UNITED STATES
Pelfrey, Rack B., Indianapolis, IN, UNITED STATES
Carter, Jeffrey M., Anderson, IN, UNITED STATES
PI US-20070252386 Al 20071101
AI 200605-000523906 Al 20060921 (11)
PRAI 200505-000719364D 20050922 (60)
200605-000785103P 20060323 (60)
DET Utility
FS APPLICATION
LPT BOSE MCKINNEY & EVANS LLP, JAMES COLES, 135 N PENNSYLVANIA ST, SUITE
2700, INDIANAPOLIS, IN, 46204, US
CLASS Number of Claims: 31
ECL Exemplary Claims: 1
DRWN 12 Drawing Page(s)
LN.CMT 581


```

AB A fitting assembly for use with a component, such as a tank containing a fluid. The fitting assembly can be used with a pressurized tank coupled to a pressurized fluid system, including pressurized air. The fitting assembly includes a spud and a corresponding fitting wherein the spud or fitting include pins which cooperate with a corresponding groove or slot of the related spud or fitting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306776-78-3P 405263-82-9P
(intermediate product in preparation of DOITA type azamacrocyclic
prochelators for preparation of radiometal labeled mols. having improved
biol. properties)


RN 306776-78-3 USPATFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
α-[3-oxo-3-(phenylmethoxy)propyl]-, 1,4,7,10-tetrakis(1,1-
dimethylethyl) ester (CA INDEX NAME)



RN 405263-88-9 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[1-[(1,3-dimethylthoxy)carbonyl]-3-oxo-3-(phenylmethoxy)propyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

L29 ANSWER 1 OF 2 USPATFULL on STN (Continued)

PAGE 1-B




IT 405263-90-3DP, radiometal complexes 405263-91-4DP,
radiometal complexes
(preparation from DOTA type azamacrocyclic prochelators as radiometal
labeled mol. having improved biol. properties for diagnostic or
therapeutic use)

```


RN      405263-90-3    USPATFULL
CN      L-cysteinamide, N-[(4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-
tetraazacyclododec-1-yl]butyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-
tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-
(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide (9CI) (CA INDEX
NAME)

```

PAGE 1-A



L29 ANSWER 1 OF 2 USPATFULL on STN (Continued)



IT 306776-80-7P
(preparation from DOTA type azamacrocyclic prochelator and labeling with
90Y)


```

RN      306776-80-7      USP2ATFULL
CN      L-Phenylalaninamide, N-[4-carboxy-1-oxo-4-{4,7,10-tris(carboxymethyl)-
        1,4,7,10-tetraazacyclododec-1-yl}butyl]-D- $\alpha$ -aspartyl-L-tyrosyl-L-
        norleucylglycyl-L-tryptophyl-L-norleucyl-L- $\alpha$ -aspartyl- (9CI) (CA
        INDEX NAME)

```


Absolute stereochemistry.

PAGE 1-A




L29 ANSWER 1 OF 2 USPATFULL on SIN (Continued)

PAGE 2-A




RN	405263-91-4	USPATFULL
CN	L-Threonine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2-7)-disulfide (9CI) (CA INDEX NAME)	

PAGE 1-A



PAGE 2-A




IT 405263-90-3P 405263-91-4P
(preparation from DOTA type azamacrocyclic prochelators for preparation of
radiometal labeled mols. having improved biol. properties)


RN 405263-90-3 USPATFULL
 CN L-Cysteinamide, N-[(4-carboxy-l-oxo-4-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)butyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide (9CI) (CA INDEX NAME)

L29 ANSWER 1 OF 2 USPATFULL on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 405263-91-4 USPATFULL
 CN L-Threonine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2>7)-disulfide (9CI) (CA INDEX NAME)

L29 ANSWER 1 OF 2 USPATFULL on STN (Continued)


PAGE 1-A




PAGE 2-A



IT 306776-79-4P 405263-89-0P
 (preparation of DOTA type azamacrocyclic prochelators for preparation of radiometal labeled mols. having improved biol. properties)
 RN 306776-79-4 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α-(2-carboxyethyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 405263-89-0 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[1-(carboxymethyl)-2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester

L29 ANSWER 1 OF 2 USPATFULL on STN (Continued)
(CA INDEX NAME)

L29 ANSWER 2 OF 2 USPATFULL on STN


AN 2006:273911 USPATFULL
 IT Prochelator for the preparation of radiometal labeled molecules having improved biological properties
 IN MAECKE, Helmut R., Lorrach, GERMANY, FEDERAL REPUBLIC OF
 EISENWIENER, Klaus-Peter T., Bern, SWITZERLAND
 PI US-2004/0233704 A1 20061019
 AI 2001US-000533906 A1 20010511 (10)
 2001WO-EP0005483 20010511
 20060330 PCT 371 date
 PRAI 2000EP-000110084 20000512
 DT Utility
 FS APPLICATION
 LREP JOYCE VON NATZMER, Hall, Vande Sande & Pequigot, LLP, 10220 River Road, Suite 200, Potomac, MD, 20854, US
 CLMN Number of Claims: 18
 ECL Exemplary claim: 1
 DRMN 5 Drawing Page(s)
 LN.CHT 376
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Chelating compounds for labeling bioactive molecules with a radiometal, having general formula (I) in which: both Y groups may be positioned either trans as shown or cis; A is an effector molecule, such as a peptide, in particular octreotide, CCK, substance P, gastrin, a protein, in particular an antibody or enzyme, sugars or radiosensitizing agents, like doxorubicin; R is a hydrogen, a C.sub.1-C.sub.3 alkyl or a alcohol; X is a spacer, in particular (CH.sub.2).sub.n-X', in which n is 1-10 and X' is COOH, NH.sub.2, SH, OH or O-halogen, in which halogen is in particular Br, I or Cl, or a molecule of the formula (a) or of the formula (b), Y is COO-, CH.sub.2CONH.sub.2, CH.sub.2CH.sub.2OH, optionally complexed with a radiometal. ##STR1#

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 306776-78-3P 405263-88-9P
 (intermediate product in preparation of DOTA type azamacrocyclic prochelators for preparation of radiometal labeled mols. having improved biol. properties)
 RN 306776-78-3 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α-[3-oxo-3-(phenylmethoxy)propyl]-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 405263-88-9 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[1-(1,1-dimethylethoxy)carbonyl]-3-oxo-3-(phenylmethoxy)propyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

L29 ANSWER 2 OF 2 USPATFULL on STN (Continued)




IT 306776-80-7P
(preparation from DOTA type azamacrocyclic prochelator and labeling with 90Y)

RN 306776-80-7 USPATFULL
CN L-Phenylalaninamide, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-α-aspartyl-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L-α-aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L29 ANSWER 2 OF 2 USPATFULL on STN (Continued)

PAGE 2-A




RN 405263-91-4 USPATFULL
CN L-Threonine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2+7)-disulfide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 405263-90-3P 405263-91-4P
(preparation from DOTA type azamacrocyclic prochelators for preparation of radiometal labeled mols. having improved biol. properties)

RN 405263-90-3 USPATFULL
CN L-Cysteineamide, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2+7)-disulfide (9CI) (CA INDEX NAME)

L29 ANSWER 2 OF 2 USPATFULL on STN (Continued)


PAGE 1-B



IT 405263-90-3DP, radiometal complexes 405263-91-4DP,
radiometal complexes
(preparation from DOTA type azamacrocyclic prochelators as radiometal labeled mol. having improved biol. properties for diagnostic or therapeutic use)


RN 405263-90-3 USPATFULL
CN L-Cysteineamide, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2+7)-disulfide (9CI) (CA INDEX NAME)

PAGE 1-A




L29 ANSWER 2 OF 2 USPATFULL on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 405263-91-4 USPATFULL
CN L-Threonine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2+7)-disulfide (9CI) (CA INDEX NAME)

PAGE 1-A




L29 ANSWER 2 OF 2 USPATFULL on SIN (Continued)


PAGE 2-A



IT 306776-79-4P 405263-85-0P
 (preparation of DOTA type aza macrocyclic prochelators for preparation of
 radiometal labeled mols. having improved biol. properties)
 RN 306776-79-4 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
 9-(2-carboxyethyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester
 (CA INDEX NAME)



RN 405263-89-0 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[1-(carboxymethyl)-
 2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester
 (CA INDEX NAME)



=> d bib abs hitstr 134 tot

L34 ANSWER 1 OF 13 USPATFULL on SIN
 AN 200040666 USPATFULL
 TI Liposomal agents
 IN Garrity, Martha, Wayne, PA, United States
 Varadarajan, John, Wayne, PA, United States
 Watson, Alan David, Wayne, PA, United States
 PA Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)
 PI US-----6045821 20009404 <--
 WO-----9611023 19960418 <--
 AI 1997US-000809729 19970529 (8)
 1995WO-GB0002378 19951009
 19970529 PCT 371 date
 19970529 PCT 102(e) date

PRAI 1994GB-000020390 19941010
 DT Utility
 FS Granted

EXNAM Primary Examiner: Kishore, Gollamudi S.
 LREP Bacon & Thomas

CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN No Drawings

LN.CNT 1316

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a liposomal agent comprising liposomes having bound to a membrane thereof a chelated diagnostically or therapeutically effective metal ion. The chelating agent binding the metal ion has a macrocyclic chelant moiety with, attached to a single ring atom thereof, a lipophilic membrane associating moiety.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 173308-18-4P

(preparation and reaction; chelate-containing liposomal agents, and their preparation, for diagnostic imaging and therapeutic use)

RN 173308-18-4 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris(1,1-dimethylethyl) methyl ester (9CI) (CA INDEX NAME)



L34 ANSWER 2 OF 13 USPATFULL on SIN
 AN 1999132199 USPATFULL
 TI Dichelants
 IN Carvalho, Joan, Mountain View, CA, United States
 Watson, Alan D., Campbell, CA, United States
 Fellmann, Jere D., Livermore, CA, United States
 Koo, Michael, San Jose, CA, United States
 PA Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)
 PI US-----5972307 19991026 <--
 AI 1997US-000898376 19970722 (8)
 RLI Division of Ser. No. 1994US-000226760, filed on 12 Apr 1994, now patented, Pat. No. US-----5650133 which is a continuation-in-part of Ser. No. 1993US-00086996, filed on 7 Jul 1993, now patented, Pat. No. US-----5446145 which is a continuation-in-part of Ser. No. 1990US-000468107, filed on 19 Jan 1990, now patented, Pat. No. US-----5281704, said Ser. No. US 226760 which is a continuation-in-part of Ser. No. 1992US-000885028, filed on 12 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 468107

PRAI 1993GB-000020277 19931001

DT Utility
 FS Granted

EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Hartley, Michael G.

LREP Fish & Richardson P.C.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1802

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to dichelants, in particular compounds having two macrocyclic chelant groups linked by a bridge containing an ester or amide bond, especially compounds of formula Vb ##STR1## (wherein each X which may be the same or different is NE, O or S, at least two Xs being NE;

each Z is a group R.sub.1 or a group CR.sub.1.sub.2 Y, at least one Z, and preferably 2 or 3 Zs, on each macrocyclic ring being a group CR.sub.1.sub.2 Y;

each Y is a group CO.sub.2 H, PO.sub.3 H, SO.sub.3 H, CONR.sub.1.sub.2, CON(OR.sub.1)R.sub.1, CNS or CONR.sub.1 NR.sub.1.sub.2, preferably COOH;

m is 0 or 1 or 2, preferably 1; each n is 2 or 3, preferably 2; q is 1 or 2, preferably 1;

each R.sub.1 which may be the same or different is a hydrogen atom or an alkyl group optionally substituted by one or more hydroxy and/or alkoxy groups;

and D is a bridging group having a molecular weight of less than 1000, preferably less than 500, joining two macrocyclic rings via at least one amide or ester bond) and salts and metal chelates thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 137076-50-7P

(preparation of, in polychelant chelating agent preparation)

RN 137076-50-7 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl ester (9CI) (CA INDEX NAME)

L34 ANSWER 2 OF 13 USPATFULL on SIN (Continued)



L34 ANSWER 3 OF 13 USPATFULL on SIN
 AN 199975290 USPATFULL
 TI Polyaminated ligands and metal complexes thereof
 IN Meyer, Dominique, Saint-Maur, France
 Rousseaux, Olivier, Senlis, France
 Schaefer, Michel, Lagny, France
 Simonot, Christian, Paris, France
 Guerbet S.A., Villepinte, France (non-U.S. corporation)
 PA US-----5919432 19990706 <--
 PI 1997US-000590823 19971028 (8)
 RLI Division of Ser. No. 1997US-000808568, filed on 28 Feb 1997, now patented, Pat. No. US-----5712389 which is a continuation of Ser. No. 1994US-000366732, filed on 30 Dec 1994, now abandoned

PRAI 1993PE-000015933 19931230

DT Utility
 FS Granted

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Sripada, Pavanaram K.

LREP Jacobson, Price, Holman & Stern PLLC

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Poly(amino acid) derivatives, which are chelating agents of paramagnetic metal ions, in which at least 3 of the donor nitrogen atoms carry identical or different substituents, of Formula

CH(R.sub.1)--X,


in which X represents CO.sub.2 R.sub.2, a, R.sub.2, b and R.sub.2, c or P(R.sub.2.d)O.sub.2 H and R.sub.2, a, R.sub.2, b and R.sub.2, c, which are identical or different, represent H or optionally hydroxylated (C.sub.1 -C.sub.8)alkyl, R.sub.2, d represents OH, (C.sub.1 -C.sub.8)alkyl or (C.sub.1 -C.sub.8)alkoxy and R.sub.1 represents a hydrophilic group with a molecular weight greater than 200 containing at least 3 oxygen atoms, with the proviso that at least 3 of the X groups are optionally sulfated acid functional groups.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 167272-14-2P (for preparation of paramagnetic metal complexes as NMR imaging agents)

RN 167272-14-2 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 6,6',9,9'-tetrakis(3-aminopropyl)-tetrakis(1-methylethyl) ester, tetrahydrochloride (9CI) (CA INDEX NAME)



●4 HCl


IT 167272-21-1P 167272-22-2P

(for preparation of tetraazacyclododecane derivative complexes with paramagnetic metal ions as NMR imaging agents)


RN 167272-21-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,

L34 ANSWER 3 OF 13 USPATFULL on STN (Continued)
 6,6',6'',6'''-tetrakis[3-(1,3-dihydro-1,3-dioxo-2H-indol-2-yl)propyl]-, tetrakis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 167272-22-2 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrabutanoic acid, 7,7',7'',7'''-tetrakis(methoxycarbonyl)-, tetramethyl ester (9CI) (CA INDEX NAME)




IT 167272-21-1DP, gadolinium complexes (preparation as NMR imaging agents)
 RN 167272-21-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 6,6',6'',6'''-tetrakis[3-(1,3-dihydro-1,3-dioxo-2H-indol-2-yl)propyl]-, tetrakis(1-methylethyl) ester (9CI) (CA INDEX NAME)

L34 ANSWER 4 OF 13 USPATFULL on STN
 AN 1999:37270 USPATFULL
 TI Metal complexes of polyamino oxides, and their utilization in diagnostic imaging
 IN Meyer, Dominique, Saint Maur, France
 Rousseaux, Olivier, Senlis, France
 Schaefer, Michel, Lagny, France
 Simonot, Christian, Paris, France
 PA Guerbet S.A., Villepinte, France (non-U.S. corporation)
 PI US-----5886158 19990323 <--
 WO-----9701359 19970116 <--
 AI 1997US-000981022 19971229 (8)
 1996WO-FR0000992 19960625
 19971229 PCT 371 date
 19971229 PCT 102(e) date
 PRAI 1995FR-000007860 19950629
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Jones, Dameron
 LREP Jacobson, Price, Nolman & Stern, PLLC
 CLMN Number of claims: 7
 ECL Exemplary claim: 1
 DRWN No Drawings
 LN.CNT 420
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention concerns gadolinium complexes of formula: ##STR1## in which R represents a group of formula: ##STR2## in which X is Br or I; R.sub.1 is H or optionally hydroxylated alkyl; R.sub.2 is hydroxylated alkyl; or alternatively R.sub.1 is H and R.sub.2 is a group of formula: ##STR3## X being as defined above, and R'.sub.1 and R'.sub.2 being as defined for R.sub.1 and R.sub.2 excepted that they do not represent A, provided that --CO--NR'.sub.1 R'.sub.2 or --CO--NR'.sub.1 R'.sub.2 comprises at least 2 hydroxyl groups, and M represents H or the cation of an inorganic or organic base.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 167272-22-2P
 (for preparation of gadolinium tetraazamacrocyclic poly(amino acid) complexes as MRI contrast agents)
 RN 167272-22-2 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrabutanoic acid, 7,7',7'',7'''-tetrakis(methoxycarbonyl)-, tetramethyl ester (9CI) (CA INDEX NAME)




L34 ANSWER 5 OF 13 USPATFULL on STN (Continued)



L34 ANSWER 5 OF 13 USPATFULL on STN
 AN 1998:138472 USPATFULL
 TI Dendrimeric compounds
 IN Margerum, Larry, Wayne, PA, United States
 Campion, Brian, Solano Beach, CA, United States
 Fellmann, Jere Douglas, Livermore, CA, United States
 Garrity, Martha, San Clemente, CA, United States
 PA Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)
 PI US-----5834020 19981110 <--
 WO-----9528966 19951102 <--
 AI 1997US-000722082 19970121 (8)
 1995WO-GB0000898 19950420
 19970121 PCT 371 date
 19970121 PCT 102(e) date
 PRAI 1994GB-000007812 19940420
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Levy, Neil S.
 LREP Fish & Richardson P.C.
 CLMN Number of claims: 17
 ECL Exemplary claim: 1
 DRWN No Drawings
 LN.CNT 2049
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides a dendrimeric compound comprising a dendrimeric bioactive moiety with linked thereto a plurality of diagnostically or therapeutically active moieties characterized in that the molecular skeleton of said compound contains at least one biodegradable cleavage site such that on cleavage thereof said active moieties are released in renally excretable form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 173308-18-4P
 (preparation of gadolinium complexes as contrast agents)
 RN 173308-18-4 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris(1,1-dimethylethyl) methyl ester (9CI) (CA INDEX NAME)



L34 ANSWER 6 OF 13 USPATFULL on STN
 AN 1998:9610 USPATFULL
 TI Polyaminated ligands and metal complexes thereof
 IN Meyer, Dominique, Saint-Maur, France
 Rousseau, Olivier, Senlis, France
 Schaefer, Michel, Lagny, France
 Simonot, Christian, Paris, France
 PA Guerbet S.A., Villepinte, France (non-U.S. corporation)
 PI US-----571389 19980127 <--
 AI 1997US-000808568 19970228 (8)
 RLI Continuation of Ser. No. 1994US-000366732, filed on 30 Dec 1994, now abandoned
 PRAI 1993FR-000015933 19931220
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Sripada, Pavanaram K.
 LREP Jacobson, Price, Holman & Stern, PLLC
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1035


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Poly(amino acid) derivatives, which are chelating agents of paramagnetic metal ions, in which at least 3 of the donor nitrogen atoms carry identical or different substituents, of formula

CH (R.sub.1) --X,

in which X represents CO.sub.2 R.sub.a, CONR.sub.b R.sub.c or P(R.sub.d)O.sub.2 H and R.sub.a, R.sub.b and R.sub.c, which are identical or different, represent H or optionally hydroxylated (C.sub.1 -C.sub.8)alkyl, R.sub.d represents OH, (C.sub.1 -C.sub.8)alkyl or (C.sub.1 -C.sub.8)alkoxy and R.sub.1 represents a hydrophilic group with a molecular weight greater than 200 containing at least 3 oxygen atoms, with the proviso that at least 3 of the X groups are optionally salified acid functional groups.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167272-14-2P
 (for preparation of paramagnetic metal complexes as NMR imaging agents)
 RN 167272-14-2 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
 9,9',9'',9'''-tetrakis(3-aminopropyl)-,
 tetrakis(1-methylethyl) ester, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl

IT 167272-21-1P 167272-22-2P
 (for preparation of tetraazacyclododecane derivative complexes with paramagnetic

L34 ANSWER 6 OF 13 USPATFULL on STN (Continued)
 metal ions as NMR imaging agents)
 RN 167272-21-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
 9,9',9'',9'''-tetrakis(3-(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)propyl)-, tetrakis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 167272-22-2 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrabutanoic acid,
 7,7',7'',7'''-tetrakis(methoxycarbonyl)-,
 tetramethyl ester (9CI) (CA INDEX NAME)



IT 167272-21-10P, gadolinium complexes
 (preparation as NMR imaging agents)


RN 167272-21-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
 9,9',9'',9'''-tetrakis(3-(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)propyl)-, tetrakis(1-methylethyl) ester (9CI) (CA INDEX NAME)

L34 ANSWER 6 OF 13 USPATFULL on STN (Continued)



L34 ANSWER 7 OF 13 USPATFULL on STN
 AN 97:96997 USPATFULL
 TI Linear oligomeric polychelant compounds
 IN Lowe, David B., Wayne, PA, United States
 Dow, William C., Wayne, PA, United States
 Himmelsbach, Richard J., Wayne, PA, United States
 Watson, Alan D., Wayne, PA, United States
 Rocklage, Scott M., Wayne, PA, United States
 PA Salutar, Inc., Sunnyvale, CA, United States (U.S. corporation)
 PI US-----5679810 19971021 <--
 AI 1995US-000480056 19950607 (8)
 RLI Continuation-in-part of Ser. No. 1993US-00086996, filed on 7 Jul 1993, now patented, Pat. No. US-----546146 which is a division of Ser. No. 1990US-000468107, filed on 19 Jan 1990, now patented, Pat. No. US-----5281704
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Gupta, Yogendra N.
 LREP Fish & Richardson PC
 CLMN Number of Claims: 12
 ECL Exemplary claim: 1
 DRWN No Drawings
 LN.CNT 1846
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Linear oligomer polychelant compounds and chelates formed therewith have alternating chelant and linker moieties bound together by amide or ester moieties. The compounds have between 3 and 100 chelant moieties, at least one of which complexes a paramagnetic metal ion. The polychelants and especially their paramagnetic metal polychelates are particularly suitable for diagnostic imaging.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 137076-50-7P
 (preparation of linear oligomeric polychelant polyaminocarboxylic acids and their paramagnetic metal chelates for diagnostic imaging)
 RN 137076-50-7 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl ester (9CI) (CA INDEX NAME)




L34 ANSWER 8 OF 13 USPATFULL on STN
 AN 9634691 USPATFULL
 TI Triaza macrocycles
 IN Parker, David, Durham, United Kingdom
 Beeley, Nigel P. A., Thame, United Kingdom
 Millican, Thomas A., Maidenhead, United Kingdom
 PA Celitech Therapeutics Limited, Slough, United Kingdom (non-U.S. corporation)
 PI US-----5345362 19961015 <--
 AI 1995US-000467913 19950606 (8)
 RLI Continuation of Ser. No. 1992US-000946508, filed on 18 Sep 1992, now abandoned which is a division of Ser. No. 1992US-000817999, filed on 9 Jan 1992, now abandoned which is a continuation of Ser. No. 1990US-000601700, filed on 30 Oct 1990, now abandoned
 PRAI 1989GB-000002024 19890210
 1989GB-000003025 19890210
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Datlow, Philip I.
 LREP Mathews, Woodbridge & Collins
 CLMN Number of Claims: 10
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 570

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Triaza macrocycles carrying a -CH.sub.2 COOH, -CH.sub.2 CONR.sup.6 R.sup.7, -CH.sub.2 P(R.sup.5)O.sub.2 H, or -CH.sub.2 PO.sub.3 H.sub.2 group on two of the three ring nitrogen atoms and a -CH(L-2)COOH, -CH(L-2)CONR.sup.6 R.sup.7, -CH(L-2)P(R.sup.5)O.sub.2 H, or -CH(L-2)PO.sub.3 H.sub.2 group on the third ring nitrogen atom, in which L is an organic linking radical and Z is any group capable of reacting with a thiol, amino, carbonyl, hydroxyl, aldehyde, aromatic, or heteroaromatic group, and metal complexes thereof, are useful for imaging, diagnosis, and therapy. A typical embodiment is N-[5-carboxy-5-(4,7-bis-(carboxymethyl)-2,4,7-triazacyclonon-1-yl)pentyl] 3-maleimidopropionamide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 132262-07-8P
 (preparation of, for imaging and treatment of tumor)
 RN 132262-07-8 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 9-[4-(benzylamino)butyl]-, tetraethyl ester (9CI) (CA INDEX NAME)




L34 ANSWER 9 OF 13 USPATFULL on STN
 AN 9578284 USPATFULL
 TI Polychelant compounds
 IN Love, David B., Campbell, CA, United States
 Dow, William C., Fremont, CA, United States
 Himmelsbach, Richard J., Pleasanton, CA, United States
 Watson, Alan D., Campbell, CA, United States
 Rocklage, Scott M., Los Gatos, CA, United States
 PA Nycomed Salutar, Inc., Sunnyvale, CA, United States (U.S. corporation)
 PI US-----5446145 19950829 <--
 AI 1993US-000086996 19930707 (8)
 RLI Division of Ser. No. 1990US-000466107, filed on 19 Jan 1990, now patented, Pat. No. US-----5281704
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Gupta, Y. N.
 LREP Lyon & Lyon
 CLMN Number of Claims: 13
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed polychelant compounds, that is multi-site metal chelating agents, and chelates formed therewith. The polychelants and especially their paramagnetic metal, heavy metal or radioactive metal polychelates are particularly suitable for use in diagnostic imaging, heavy metal detoxification or radiotherapy. The polychelants have a linear or branched oligomeric structure comprising alternating chelant and linker moieties bound together by amide or ester moieties. The carbonyl groups whereof being adjacent the chelant moieties, each polychelant comprising at least two said chelant moieties capable of complexing a metal ion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 137076-50-7P
 (preparation of, in polychelant chelating agent preparation)
 RN 137076-50-7 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl ester (9CI) (CA INDEX NAME)




L34 ANSWER 10 OF 13 USPATFULL on STN
 AN 94193084 USPATFULL
 TI Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
 IN Desreux, Jean F., Angleur, Belgium
 Tweedle, Michael F., Princeton, NJ, United States
 Ratsep, Peter C., Hamilton Square, NJ, United States
 Wagler, Thomas R., Princeton, NJ, United States
 Mazinelli, Edmund R., Lawrenceville, NJ, United States
 PA Bristol-Myers Squibb, Princeton, NJ, United States (U.S. corporation)
 PI US-----5358704 19941025 <--
 AI 1993US-000129870 19930930 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Hollinden, Gary E.
 LREP Kilcoyne, John M.
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds of the formula *#87A1* and metal chelates of the compounds are useful particularly for MRI of the hepatobiliary system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 160113-00-8P
 (preparation of tetraazamacrocyclic chelates for magnetic resonance contrast agents for hepatobiliary system)
 RN 160113-00-8 USPATFULL
 CN Dibenzo[b,h][1,4,7,10]tetraazacyclododecane-5,8,13,16-tetraacetic acid, hexadecanoyldro-, tetrakis[2-oxo-2-(phenylmethoxy)ethyl] ester, (4aR*,6aR*,12aS*,16aR*)- (9CI) (CA INDEX NAME)
 Relative stereochemistry.




L34 ANSWER 11 OF 13 USPATFULL on STN
 AN 94153282 USPATFULL
 TI Chelating compounds
 IN Klaveness, Jo, Oslo, Norway
 PA Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)
 PI US-----5322681 19940621 <--
 AI 1992US-00010318 19920717 (7)
 PRAI 1990GB-000001246 19900119
 1990GB-000007984 19900409
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Ford, John M.; Assistant Examiner: Stripada, P. K.
 LREP Bacon & Thomas
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 823

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention provides novel condensed macrocyclic chelants of formula [X(CR.sup.2 R.sup.3).sub.n].sub.m, (wherein each X independently represents an oxygen or sulphur atom or a group of formula NR, N(CR.sup.2 R.sup.3).sub.p R.sup.4, N(CR.sup.2 R.sup.3).sub.p Y, or N(CR.sup.2 R.sup.3).sub.n- N(CR.sup.2 R.sup.3).sub.p Y).sub.2; each Y independently represents a group COO, SO.sub.2 Z, POO.sub.2, CON(OH)R.sup.2, CH.sub.2 SR.sup.2, CS.sub.2 R.sup.2 or CS2; each Z independently represents a group OR.sup.2 or NR.sup.2 R.sup.2; n is an integer of 1 to 4; m is an integer of 3 to 8; p is an integer of 1 to 3; each R.sup.2 independently represents a hydrogen atom or a C.sub.1-8 alkyl group optionally mono- or poly-substituted by hydroxyl or C.sub.1-8 alkoxy groups and at least one pair of R.sup.2 groups, in each pair one being from a (CR.sup.2 R.sup.3).sub.p Y moiety and the other being from a (CR.sup.2 R.sup.3).sub.n- N(CR.sup.2 R.sup.3).sub.p Y moiety, together with the intervening atoms represents a 5 to 8 membered, saturated fused ring optionally containing one or more ring heteroatoms selected from nitrogen, oxygen and sulphur, said fused ring optionally being substituted by a group R.sup.1; each R.sup.1 independently represents a group R.sup.4 or a nitrogen-attached group (CR.sup.2 R.sup.3).sub.p Y; each R.sup.3 independently represents a hydrogen atom or a C.sub.1-8 alkyl or C.sub.1-8 alkoxy group optionally mono or poly substituted by hydroxyl or C.sub.1-8 alkoxy groups; and each R.sup.4 independently represents a hydrogen atom, a halogen atom or a hydroxyl group or an optionally mono- or poly-hydroxylated C.sub.1-8 alkyl, C.sub.1-8 alkoxy, (C.sub.1-8 alkoxy)-C.sub.1-8 alkyl or poly-(C.sub.1-8 alkoxy)-C.sub.1-8 alkyl group, a sulphonate group or a group (CR.sup.2 R.sup.3).sub.p Y; with the proviso that at least 2 Y groups are present). These chelants are useful in the preparation of diagnostic and therapeutic agents, in particular chelate complexes suitable for use as contrast agents for diagnostic imaging techniques, e.g. MRI.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 136582-74-6P
 (preparation and deprotection of)
 RN 136582-74-6 USPATFULL
 CN 13-Oxa-3,6,9,15-tetraazabicyclo[9.3.1]pentadecane-3,6,9,15-tetraacetic acid, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



134 ANSWER 12 OF 13 USPATFULL on STN
 RN 94:7797 USPATFULL
 TI Polychelant compounds
 IN Love, David B., Campbell, CA, United States
 Dow, William C., Fremont, CA, United States
 Himmelsbach, Richard J., Pleasanton, CA, United States
 Watson, Alan D., Campbell, CA, United States
 Rocklage, Scott M., Los Gatos, CA, United States
 Salutar, Inc., Sunnyvale, CA, United States (U.S. corporation)
 PA US-----5281704 19940125 <--
 AT 1390US-000468107 19900119 (7)
 PRAI 1989GB-00023843 19891023
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Ward, E. C.
 CLMN Number of Claims: 25
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN CNT 1759
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB There are disclosed polychelant compounds, that is multi-site metal chelating agents, and chelates formed therewith. The polychelants and especially their paramagnetic metal, heavy metal or radioactive metal polychelates are particularly suitable for use in diagnostic imaging, heavy metal detoxification or radiotherapy. The polychelants have a linear or branched oligomeric structure comprising alternating chelant and linker moieties bound together by amide or ester moieties the carbonyl groups whereof being adjacent the chelant moieties, each polychelant comprising at least two said chelant moieties capable of complexing a metal ion.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 137076-50-7P (preparation of, in polychelant chelating agent preparation)
 RN 137076-50-7 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl ester (PCI) (CA INDEX NAME)




134 ANSWER 13 OF 13 USPATFULL on STN
 RN 91:80552 USPATFULL
 TI Chelating agents
 IN Dean, Richard T., Downingtown, PA, United States
 Weber, Robert W., Downingtown, PA, United States
 PA Centocor, Malvern, PA, United States (U.S. corporation)
 PI US-----5053503 19911001 <--
 AT 1989US-000312767 19890217 (7)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Springer, David B.
 LREP Woodcock Washburn Kurtz Mackiewicz & Norris
 CLMN Number of Claims: 23
 ECL Exemplary Claim: 1,22,23
 DRWN No Drawings
 LN CNT 604
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A bifunctional chelating agent for joining an antibody or antibody fragment and a metallic radionuclide is disclosed. The agent consists of a derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid or a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, an organic linking radical which optionally contains a cleavable group, and a function capable of reacting with a site on a protein. Radiodiagnostic or radiotherapeutic precursors comprising an antibody or antibody fragment and the above-described bifunctional chelating agent and radiodiagnostic or radiotherapeutic agent comprising a metallic radionuclide and the above mentioned precursor are also disclosed.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 139085-84-0P 139085-86-2P (preparation of, as intermediate for chelating agents-protein conjugates)
 RN 139085-84-0 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[6-oxo-6-(phenylmethoxy)hexyl]-, tris(1,1-dimethylethyl) ester (PCI) (CA INDEX NAME)




RN 139085-86-2 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[6-[2-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)ethoxy]ethoxy]-6-oxohexyl]-, tris(1,1-dimethylethyl) ester (PCI) (CA INDEX NAME)

134 ANSWER 13 OF 13 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 2-A



=> d his

(FILE 'HOME' ENTERED AT 15:49:45 ON 10 JUN 2008)

FILE 'HCAPLUS' ENTERED AT 15:49:57 ON 10 JUN 2008

L1 1 US20060233704/PN

FILE 'REGISTRY' ENTERED AT 15:50:03 ON 10 JUN 2008

FILE 'HCAPLUS' ENTERED AT 15:50:03 ON 10 JUN 2008

L2 TRA L1 1- RN : 31 TERMS

FILE 'REGISTRY' ENTERED AT 15:50:03 ON 10 JUN 2008

L3 31 SEA L2

L4 STR

L5 5 L4

L6 599 L4 FULL

SAV TEM L6 J906C1G1/A

L7 7 L6 AND L3

L8 STR L4

L9 7 L8 SAM SUB=L6

L10 170 L8 FULL SUB=L6

SAV TEM J906C1G1S1/A L10

L11 4 L10 AND L3

L12 7 L7,L11

L13 166 L10 NOT L12

FILE 'HCAPLUS' ENTERED AT 16:07:59 ON 10 JUN 2008

L14 4 L12

L15 116 L13

L16 36 L15 AND PD<=20000512

L17 32 L15 AND PD<=19990512

L18 40 L15 AND (PRD<=20010511 OR AD<=20010511)

L19 36 L16-17

L20 15 L19 NOT L18

L21 36 L19-20

FILE 'HCAOLD' ENTERED AT 16:11:00 ON 10 JUN 2008

L22 0 L12

L23 0 L13

FILE 'HCAPLUS' ENTERED AT 16:15:41 ON 10 JUN 2008

L24 19 L18 NOT L21

SEL HIT RN

FILE 'REGISTRY' ENTERED AT 16:16:12 ON 10 JUN 2008

L25 23 E1-23

L26 67 E24-90

L27 1 L26 AND C35H58N4O8

FILE 'HCAPLUS' ENTERED AT 16:25:56 ON 10 JUN 2008

L28 2 L27 AND L21

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 16:27:25 ON 10 JUN 2008

L29 2 L12

L30 100 L13

L31 13 L30 AND PD<=20000512

L32 11 L30 AND PD<=19990512

L33 72 L30 AND (PRD<=20010511 OR AD<=20010511)

L34 13 L31-32

=>